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Frequency and sensitivity pattern of Extended Spectrum Beta Lactamase produc-
ing isolates in a tertiary care hospital laboratory of Pakistan
Kausar Jabeen, Afia Zafar, Rumina Hasan
Department of Pathology, The Aga Khan University Hospital, Karachi, Pakistan.
Abstract
Objective: To determine frequency, distribution and sensitivity pattern of Extended-Spectrum ß Lactamase
(EBSL) producing organism at a tertiary care hospital in Pakistan.
Methods: All members of enterobacteriacae isolated between April and August 2002 were studied. Isolates were spe-
ciated according to standard biochemical tests. Susceptibility testing was performed by Kirby-Bauer method. ESBL
was detected using double disc method using cefotaxime versus cefotaxime plus clavulanate according to NCCLS.
Statistical analysis was performed by SPSS version 10. Test of significance were calculated using chi-square test.
Results: During the study period, 1137/2840 (40%) of the isolates tested were found to be ESBL producing. ESBL
positivity was detected in 50% Enterobacter sp., 41% E.coli and 36% K.pneumoniae. ESBL production was noted in
52% of nosocomial isolates tested (415/799). ESBL was more frequent in patients at the extremes of ages (under 5
years and more than 60 years). Cross-resistance to non-beta lactam antibiotics (flouoroquinolones, aminoglycosides
and co-trimoxazole) was also more frequent in ESBL producing organisms (p<0.05). 
Conclusion: A high frequency of ESBL positivity amongst our isolates is documented which is alarming in low-
income settings where expensive second line agents are unavailable. Our data supports urgent need for regu-
lar screening and surveillance for these organisms (JPMA 55:436;2005).
Introduction
Extended-spectrum ß-lactamase (ESBL) producing
organisms are a major problem in the area of infectious dis-
ease1 conferring resistance to all ß-lactam antibiotics except
cephamycins and carbapenems.2 In addition, ESBL-produc-
ing organisms frequently show cross-resistance to many
other classes of antibiotics; including aminoglycosides and
fluoroquinolones3 thus treatment of these infections is often
a therapeutic challenge.
The frequency of ESBL-producing organisms dif-
fers significantly in accordance with geographic location.4-
6 The ESBL positivity rate amongst K.pneumoniae is
reported at 45% in Latin America and 7% in the United
States. In New York, on the other hand, surveillance of 15
hospitals in Brooklyn report, 34% ESBL positivity was
found in K. pneumoniae.5 Similarly, although frequency of
ESBL producing E.coli in Europe, North, Latin America
and Western Pacific is reported at 1-8%4, its prevalence in
the Asia Pacific region and South Africa is reported at
more than 20%.7 Mathur et al from India recently reported
68% ESBL positivity rate in their enterobacteriacae iso-
lates8 while Shah et al and Zaman et al have reported a fre-
quency of 48% and 35% respectively from Pakistan
(Table).9,10
Detection of ESBL is a major challenge for the clin-
ical microbiology laboratory.11 Its presence in bacterial
cells does not always produce phenotypic resistance result-
ing in some ESBL isolates appearing susceptible to third-
generation cephalosporin in vitro. However treatment of
these isolates with third-generation cephalosporins is fre-
quently ineffective.12,13
A proficiency testing project for clinical laborato-
ries participating in the National Nosocomial Infections
Surveillance System indicated that as many as 58% of
laboratories failed to detect and report ESBL isolates cor-
rectly.14 In some studies, 37% of ESBL producing organ-
isms were misreported15 whereas in another study only 7
out of 38 laboratories correctly identified and reported
these organisms.16 These data suggest that improvement
in the ability of clinical laboratories to detect ESBLs is
needed. National Committee for Clinical Laboratory
Standards (NCCLS) and British Society for Antimicrobial
and Chemotherapy (BSAC) have published standardized
criteria for screening, confirmatory testing and reporting
of these organisms.17,18 All ESBL producing organisms
Table. Reported ESBL positivity rates from Asia.
Year Country % (n) (ESBL) Reference 
 
2002 Pakistan 48 (400) 9 
2002 China, Japan, Taiwan, 
Singapore, Philippine  
>20 (2193) 7 
2002 India 68 (678) 8 
2000 Hong Kong 11-13 (1174) 25 
1999 Pakistan 35 (200) 10 
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should be reported as being resistant to all peni-
cillins, cephalosporins and aztreonam.
In developing countries, many laboratories do not
routinely detect ESBL production, a practice which is
likely to result in misreporting and hence treatment fail-
ures. On the other hand, in areas with low ESBL levels it
may not be cost effective to test for ESBL on a routine
basis.19 It is therefore essential that ESBL positivity rates
are monitored and that decision regarding appropriate lab-
oratory practices made in light of local/regional ESBL
data. Moreover correct reporting would limit inappropri-
ate antimicrobial usage and hence decrease emergence
and extension of antimicrobial resistance worldwide. In
this paper, ESBL positivity rates among isolates from
Karachi, Pakistan are discussed along with implications
with regard to laboratory practices in developing coun-
tries. Therefore frequency, distribution and sensitivity
pattern of EBSL producing organism in samples submit-
ted to a tertiary care referral hospital laboratory was
determined. 
Material and Methods
This descriptive study was performed at a 550 bed
tertiary care hospital located in Karachi, Pakistan. Clinical
microbiology laboratory of the hospital receives samples
from in and outpatients presenting to the tertiary care centre
as well as from referrals other hospitals, clinics and general
practitioners across the city.
All enterobacteriacae isolated between April to
October 2002 (2840 isolates) were studied for ESBL pro-
duction. These included 1248 isolates from patients present-
ing to our hospital (including inpatients, and patients from
emergency room, consulting clinics as well as from our
community health centre). While 1590 isolates were from
referrals outside (i.e. from other hospitals, clinics and gen-
eral practitioners across the city). 
Enterobacteriaceae growing in clinical speci-
mens were identified using routine biochemical tests.20
Kirby Bauer was performed in accordance with NCCLS
guidelines17 using Mueller Hinton agar (Oxoid). ESBL
detection method used was double disc method using
cefotaxime (30 µg) in comparison to cefotaxime plus
clavulanate (30+10 µg) (Oxoid) according to NCCLS
criteria.17
SPSS version 10 was used to enter and analyze data.
Descriptive analysis was carried out and test of significance
was calculated using chi-square test.
Results 
During the study period 2840 isolates of enter-
obacteriaceae were identified. Of these, 2016 (71%) were
E.coli, 429 (15%) K.pneumonae and 256 (9%)
Enterobacter sp. Overall 1137/2840 (40%) were ESBL
producing. The sources of ESBL positive isolates includ-
ed urine (n=784), blood (n=119), sterile body fluids (CSF,
pleural and peritoneal fluids) (n= 86), respiratory speci-
m e n s
(n= 62) and central lines (n=20). Frequency of ESBL pos-
itivity was highest amongst Enterobacter species 50%
(n=256) followed by E.coli 41% (n=2016), Klebsilla
species 36% (n=429), Morganella species 27% (n=111),
Proteus species 20% (n=51) with Citrobacter sp. showing
the lowest positivity rate 14% (n=22).
Out of 2840 enterobacteriaceae isolates, 1248 iso-
lates from patients presenting to the tertiary care centre
itself were further analyzed in terms of location and ESBL
positivity. Unfortunately, the remaining isolates from out-
side referrals could not be analyzed due to incomplete clin-
ical information. While ESBL positivity was more than
30% in all study areas, highest positivity rate 52% (n=799)
was significantly noted amongst inpatient isolates. The
positivity rate was also high in isolates from the emergency
room 45% (n=269) and consulting clinics 39% (n=140).
Whereas ESBL isolation rate was significantly lower, 30%
(n= 40) in community health centre patients as compared to
inpatients. (p>0.01)
Age wise break up of ESBL positivity rate is
shown in Figure 1. Mean age of patients with ESBL pro-
ducing organisms was 47 (Range: 1-95) versus 43
(Range 1-100) for non ESBL producers (p<0.01).
Furthermore ESBL production is significantly more in
patients less than 5 years and more than 60 years of age
(p<0.01) (Figure 1). 
Figure 1. Age wise distribution of ESBL producing organisms exhibiting increase frequency of
ESBL isolates at extremes of ages. % ESBL isolates represents ESBL positive isolates divided by
total number of isolates obtained from a particular age group. 
An analysis of cross resistance to other antibiotics
amongst ESBL producing isolates showed that ESBL
positive isolates had significantly higher resistance to
other classes of antibiotics; aminoglycosides, quinolones
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and cotrimoxazole (p<0.01) (Figure 2). No resist-
ance was seen to carbapenems and only 23 (1%) isolates
were resistant to piperacillin/tazobactam. 
Discussion
ESBL producing organisms are among the fastest
growing problems in the area of infectious diseases. Clinical
microbiological laboratories can no longer rely on simple in
vitro susceptibility data in the absence of the proper detec-
tion of ESBL. Two other studies from Pakistan9,10 have also
reported high frequencies of ESBL positivity rate. Shah et al
from Pakistan reported that 48% of their ESBL positive iso-
lates were from patients between 50-60 years of age.9 Other
studies report a mean ages of 8321 and 5822 years for ESBL
as compared to 47 years in this study. The increasing preva-
lence in the lower age group is likely to be related to the
overall increase in ESBL load in our setting, a hypothesis
supported by other surveillance studies from Asia and Asian
Pacific region reporting an alarming increase7 in ESBL pos-
itivity.  
This study observed highest positivity for ESBL
production in Enterobacter sp. followed by E.coli.
Zaman et al from Pakistan reported highest frequency of
ESBL production in Klebsiella sp. followed by E.coli.10
The SENTRY surveillance programme form Asia Pacific
and South Africa reports that most common ESBL pro-
ducer was Klebsiella sp.23 Mathur et al8 from India have
also reported Klebsiella sp. as the top ESBL producing
organism.
Antibiotic pressure is reported to result in a muta-
tion in beta lactamase gene with production of ESBL.3
Risk factors responsible for this high frequency in our set-
ting have not been determined. However, the higher posi-
tivity rate in inpatient isolates as compared to those from
patients presenting to the community health centre is like-
ly to reflect greater antibiotic pressure amongst the inpa-
tients. ESBL positivity was also high in patients from
emergency room and consulting clinics which is likely to
be a reflection of tertiary referrals and discharged inpa-
tients being seen in these areas respectively. The impor-
tance of antibiotic pressure is further supported by the
significantly higher ESBL positivity in isolates from
patients at the extremes of ages where antimicrobial usage
is likely to be higher. 
One of the dilemmas of ESBL producing organ-
ism is that they are frequently resistant to antibiotics
other than beta lactams as they contain plasmids with
genes that encode resistance to aminoglycosides,
quinolones and trimethoprim sulfmethoxazole.24 Various
studies22,23 have documented that ESBL producing
organisms showed reduced susceptibility to all antibi-
otics except amikacin and carbapenems. We note a sim-
ilar phenomenon with increased resistance to all antibi-
otics in ESBL producing organisms in comparison with
non-ESBLs. Thus treatment options in these infections
are very limited.
In conclusion, we document a high prevalence of
ESBL positivity amongst our isolates. Due to limited
resources, several laboratories in developing countries do
not routinely detect ESBL production. However, our data
supports an urgent need for regular screening and sur-
veillance for these organisms in this region. Increased
ESBL positivity in isolates from patients at the extremes
of ages most likely reflects high antimicrobial usage in
this population. Moreover, cross-resistance in ESBL pos-
itive isolates to non-beta lactam agents severely limits
therapeutic choices and is alarming particularly in low-
income settings where expensive second line agents are
unavailable. 
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